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Abstract
Kaempferia galanga L. (K. galanga L.), belonging to the Zingiberaceae family, has been widely used in Thai tradi-
tional medicine for treatment of hypertension, asthma, rheumatism, indigestion, cold and headache and relief abdominal pain.
This study aimed to investigate the effect of dichloromethane extract of K. galanga L. (DEK) and its major component ethyl-
p-methoxycinnamate (EPMC) on hepatic microsomal cytochrome P450s enzyme activities in mice. After oral administration
with DEK (100 mg/kg which is equivalent to EPMC 80 mg/kg), EPMC (120 and 160 mg/kg) for 28 consecutive days, the
microsomal P450 content decreased. The CYP1A1 and CYP2B activities significantly increased, whereas CYP2E1 activity was
significant inhibited only at the highest concentration of EPMC (160 mg/kg). None of the treatments did affect CYP1A2 and
CYP3A4 activity when compared to the control group. The results indicated that K. galanga L. and its active compound,
EPMC may participate in herbal-drug interaction and may also increase risk of toxicity and chemical carcinogenesis from
drugs and compounds that are metabolized via CYP1A1, CYP2B and CYP2E1.
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1. Introduction
Kaempferia galanga L. (K. galanga L.) (Proh Hom in
Thai name) is a plant belonging to the Zingiberaceae family.
This plant has been found in South India and Southeast Asia
such as Malaysia, Indonesia, and Thailand.  As folk medicine,
the rhizome of K. galanga L. is employed for antibacterial,
treatment of hypertension, asthma, rheumatism, indigestion,
cold and headache, relief abdominal pain and toothache
(Mustafa et al., 1996; Kanjanapothi et al., 2004; Ridtitid et
al., 2008). The volatile oil obtained from water distillation of
this plant had activity against gram-positive and gram-nega-
tive bacteria, and fungi (Tewtrakul et al., 2005). The plant
methylene chloride extract possessed amebicidal activity
(Chu et al., 1998). Aroonrerk and Kamkaen (2009) reported
the anti-inflammatory effect by inhibition of IL-6 production
by this plant. Moreover, other pharmacological actions such
as smooth muscle relaxant and vasorelaxant effects were also
reported (Mustafa et al., 1996; Othman et al., 2006). Accord-
ing to the high content of essential oil in the dried rhizome,
phytochemical studies revealed several constituents, includ-
ing the major component; ethyl-p-methoxycinnamate (EPMC),
ethyl cinnamate, p-methoxystyrene, borneol, camphene,
carene, p-methoxycinnamic acid, kaempferal and 3-carene-5-
one, carvone, methylcinnamate and eucalyptol (Kiuchi et al.,
1987; Tewtrakul et al., 2005). The ethyl-p-methoxycinnamate
obtained from methanolic extract of K. galanga L. was highly
cytotoxic  to  Hela  cells  (Kosuge  et  al.,  1985).  Moreover,
EPMC showed relatively strong anti-carcinogenic potential
in in-vitro study (Xue and Chen, 2002) and it also has activi-
*Corresponding author.
Email address: bungorn@kku.ac.th
http://www.sjst.psu.ac.thW. Sirisangtragul & B. Sripanidkulchai / Songklanakarin J. Sci. Technol. 33 (4), 411-417, 2011 412
ties against Candida albicans, and Mycobacterium tuber-
culosis (Yenjai et al., 2003).
Cytochrome P450 (CYP) plays a critical role in bio-
transformation of a wide variety of xenobiotic substances
such as therapeutic drug, carcinogen and toxicant (Omiecin-
ski et al., 1999).  In human, three CYP families, CYP1, CYP2,
and CYP3 are the most abundant of hepatic microsome CYPs
and they are active in the metabolism of several xenobiotics
(Zhou  et  al.,  2003).  In  CYP1  family,  both  CYP1A1  and
CYP1A2 subfamilies are involved in the metabolism of many
planar aromatic drugs, and are highly active in oxidation of
carcinogens (Yan and Caldwell, 2001; Guengerich, 1995). The
CYP2 family contains several subfamilies including CYP2A,
CYP2B, CYP2C, CYP2D and CYP2E. Among them, the expres-
sion of CYP2B6 is rather low compared with other human
P450s, but it is the most important CYPs, regarding to the
number  of  metabolic  pathways  of  drugs  and  xenobiotics
catalysis. It has been shown to be responsible for metaboliz-
ing over 30% of market drugs. (Zanger and Erichelbaum,
2000; Yan and Caldwell, 2001). Their role has been strongly
implicated in the metabolism of chemotherapeutic drugs such
as cyclophosphamide (Parkinson, 1996).
For the CYP 3A family, CYP 3A4 is the predominant
P450 enzyme that is responsible for approximately 50% of
P450-mediated metabolism of drugs in therapeutic use today,
implying that this enzyme is important with respect to the
action, duration and disposition of drugs and their metabo-
lites (Yan and Caldwell, 2001).
Induction and/or inhibition of CYPs by herbal medi-
cines is the important current evidence for herbal-drug inter-
action. The interaction can cause activation or inactivation of
therapeutic agents (Delgoda and Westlake, 2004). Thus, it is
important to identify the potential of herbal-drug interaction
in order to prevent adverse effect outcome in patients who
take drugs in combination with herbal supplement. More-
over, changes in some cytochrome P450 activity are involved
in chemical carcinogenesis such as CYP1A1, CYP1A2 and
CYP2E1 (Mckinnon and Miners, 2000; Carpenter and Raucy,
2000). Induction of these CYPs by herbs may increase the
risk of carcinogenesis. On the other hand, inhibition of CYPs
activity may represent anti-carcinogenic effect of herb. Since
K. galanga L. has been traditionally used as a remedy herb,
it may be involved in bioactivation and/or detoxication of
carcinogen. Thus the effects of K. galanga L. and its major
constituent, EPMC, on cytochrome P450 isoforms including
CYP1A1,  CYP1A2,  CYP2B,  CYP2E1  and  CYP3A4  were
examined in this study.
2. Materials and Methods
2.1 Chemicals
Pregnenolone  16-carbonitrile  (PCN),  potassium
chloride, tris(hydroxymethyl)-aminomethane, reduced nicoti-
namide adenine dinucleotide phosphate (NADPH), ethoxy-
resorufin (ER), methoxyresorufin (MR), penthoxyresorufin
(PR),  standard  resorufin,  p-nitrophenol,  4-nitrocatechol
(4NC), testosterone, 6-b-hydroxytestosterone, and dimethyl-
sulfoxide were purchased from Sigma Chemical Co. (St. Louis,
MO, USA). 3-methylchloranthene (3-MC) was supplied by
Eastman  (Rocchester,  USA).  Phenobarbital  (PB)  was  a
product of Avantis (USA). Pentobarbital was provided by
Abbott S.p.a, Campoverde, Lt (Italy). Potassium chloride,
glycerol, acetronitrile, ethanol, methanol and trifluoroacetic
acid were supplied by BDH (England). Silica gel for column
chromatography and silica gel, GF 254 for thin layer chroma-
tography (TLC) were purchased from Merck (Germany). All
other chemicals were analytical grade obtained from the local
distributor.  The  standard  EPMC  was  kindly  provided  by
Assoc. Prof. Dr Chavi Yenjai, Faculty of Science, Khon Kaen
University, Thailand.
2.2 Plant material
The  dried  rhizome  powder  of  K.  galanga  L.  was
obtained from the local drug store in Khon Kaen province,
Thailand (Identified by Assoc. Prof. Dr Bungorn Sripanid-
kulchai).  A  voucher  specimen  was  kept  in  our  laboratory
(HHP-07K).
2.3 Extraction of Kaempferia galanga L. and purification
of the major compound, EPMC
The  dried  rhizome  powder  of  K.  galanga  L.  was
macerated with dichloromethane (1 kg/ 2.5 liters) for 7 days.
After filtration through a Whatman No.1 filter paper, the
solvent was evaporated in a rotary evaporator (Eyela, SB-
1000, Japan). The brown jelly-like dichloromethane extract of
K. galanga L. (DEK) was kept at 4C until used. To obtain the
major compound, ethyl-p-methoxycinnamate (EPMC), the
DEK was applied to siliga gel column chromatography (70-
230 mesh) and eluted with a gradient of dichloromethane-
hexane (70:30 to 95:5). The eluted fractions were collected and
examined by TLC (silica gel, GF 254) with dichloromethane-
hexane (95:5) as a developing solvent. The fractions contain-
ing EPMC were pooled and dried. The purity of EPMC was
checked by using HPLC method as follows; HPLC (Agilent
1100 series and UV-VWD, Agilent Japan), using an isocratic
solvent, acetronitrile: methanol: 20 mM NaH2PO4 (30:40:30
v/v/v) at a flow rate of 1 ml/min, with a ThermoHypersyl-
Keystone  ODS  HYPERSYL;  5  µm,  4.6x250  mm  (Agilent,
Germany) and guard column, µBondpack 10 µm C18 (Water,
U.S.A.). The UV detection was at 270 nm. DEK gave a similar
major peak which contained 80 mg% of EPMC (Figure 1).
2.4 Experimental animals
ICR male mice at 8 weeks of age were obtained from
the  National  Laboratory  Animal  Centre,  Salaya  Mahidol
University,  Nakorn  Pathom,  Thailand.  The  animals  were
maintained  at  25±3C  with  12  h  of  dark-light  cycle,  and
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were conducted under the National Institute of Health Guide
for Care and Use of Laboratory Animals (NIH Publication
No.80-23).
Mice were randomly divided into 8 groups (N= 5) and
treated as follows: Group 1 (negative control group) was
orally administered with olive oil at 100 µl daily. Groups 2-5
were treated with specific positive inducer of each CYP
(Jarukamjorn  et  al.,  2006),  Group  2  (positive  control  for
CYP1A1 and CYP1A2 induction) was subcutaneously admin-
istered with a typical CYP inducer, 3-methylchloranthene (3-
MC) at a daily dose of 100 mg/kg for 5 days, Group 3 (positive
control for CYP2B induction) was intraperitoneally injected
with phenobarbital (PB) at a daily dose of 100 mg/kg for 5
days. Group 4 (positive control for CYP3A4 induction) was
subcutaneously administered with pregnenolone 16-carbo-
nitrile (PCN) at a daily dose of 50 mg/kg for 5 days and Group
5 (positive control for CYP2E1 induction) was orally adminis-
tered with 10% ethanol (EtOH) in drinking water for 14 days
(Forkert et al., 1991). Group 6 (DEK-treated groups) was
orally administered with DEK at a daily dose of 100 mg/kg
(equivalent to 80 mg/kg of EPMC) for 4 weeks. Groups 7-8
(EPMC-treated groups) were orally administered with EPMC
at a daily dose of 120 and 160 mg/kg for 4 weeks, respect-
ively. The animals were observed for behavioral changes over
the experimental period. At 24 h after the last of treatment,
mice were sacrificed by decapitation. After perfusion with
1.15% ice-cold KCl until the liver became pale yellow, it was
quickly removed and immediately   frozen   in liquid   nitrogen
and stored at -80C  for microsomal preparation.
2.5 Preparation of hepatic microsome
Livers were thawed and minced, and then homogen-
ized  in  3  volumes  of  ice-cold  1.15%  (W/V)  KCl  in  0.1  M
potassium phosphate buffer pH 7.4 by a motor-driven Teflon
pestle in a glass homogenizing vessel placed in an ice bath.
The crude homogenate was centrifuged at 9,000 g, 4C for
20  minutes.  The  free  lipid  layer  of  supernatant  was  then
centrifuged at 100,000 g, 4C for 1 hr.  The microsomal frac-
tion was obtained by suspension of the sediment with 0.1 M
of  potassium  phosphate  pH  7.4  containing  20%  glycerol
(v/v), 1 mM EDTA and 0.1 mM dithiotrietol. The microsomal
protein concentration was determined under the instruction
of protein assay (BioRad laboratory) with bovine serum albu-
min as a standard. The total amount of protein in the final
volume was 10-20 mg/ml. Aliquots of the microsomal fraction
were kept at -80C until further analysis.
2.6 Assessment of total P450 content and CYPs activities
The total P450 content was determined as described
by Omura and Sato (1964). CYP1A1, CYP1A2, and CYP2B
activities were determined as described by Sakuma et al.
(1999), and Jarukamjorn et al (1999) using alkoxyresorufin O-
dealkylation (AROD) activities assay. Ethoxyresorufin O-
dealkylase (EROD), methoxyresorufin O-dealkylase (MROD),
and penthoxyresorufin O-dealkylase (PROD) activities were
performed for CYP1A1, CYP1A2, and CYP2B enzymes, res-
pectively. CYP2E1 activity was determined by measurement
of p-nitrophenol hydroxylase activity. The end product, 4-
nitrocatechol was separated using reverse phase-HPLC and
monitoring at wavelength of 345 nm (Elbrabry et al., 2006,
Mischin et al., 1996). The CYP3A4 activity was examined
using  testosterone  as  a  selective  marker.  Testosterone
hydroxylation and its metabolite, 6-hydroxytestosterone,
were determined with reverse phase-HPLC and monitoring at
wavelength of 254 nm (Baltes et al., 1998). For each deter-
mination, the number of samples is specified in each figure.
2.7 Statistical analysis
All data were expressed as mean ± S.E. Statistical
analysis was performed by the analysis of variance (ANOVA)
followed by Student’s t-test, which was set at P-value lower
than 0.05.
3. Results
The effects of oral administration of dichloromethane
extract of K. galanga L. (DEK) (100 mg/kg, which is equiva-
lent to 80 mg/kg of EPMC) and ethyl-p-methoxycinnamate
(EPMC) (120 and 160 mg/kg) on body and organ weights
were observed. There was no animal death during the treat-
Figure 1. HPLC Chromatograms of standard EPMC (A) and DEK
which  contained  80  mg%  of  EPMC  (B)  using  mobile
phase containing acetronitrile: methanol: 20mM NaH2
PO4 (30:40:30) and detection at 270 nm.W. Sirisangtragul & B. Sripanidkulchai / Songklanakarin J. Sci. Technol. 33 (4), 411-417, 2011 414
ment period in any studied group. Neither DEK nor any dose
of EPMC caused any detectable changes in behavior activi-
ties. There were no changes in body, liver or kidney weights
(data not shown). The internal organs of all animals showed
no  signs  of  abnormality  in  appearance  to  the  naked  eye.
These results indicated that oral administration of DEK (100
mg/kg) and EPMC (120, 160 mg/kg) did not produce toxicity.
The treatments with DEK (100 mg/kg) and EPMC (120
and 160 mg/kg) for 28 days had significantly reduced total
microsomal P450 content. In contrast, the administrations
of  PB  and  PCN,  which  are  specific  CYP2B  and  CYP3A4
inducers, markedly increased total microsomal P450 content
up to 3.2- and 2.3-fold, respectively. Whereas the treatment
of  3-MC,  a  specific  CYP1A1  and  CYP1A2  inducer,  and
ethanol,  a  specific  CYP2E1  inducer,  did  not  affect  total
microsomal P450 content (Figure 2A).
Using ethoxyresorufin O-dealkylation (EROD as an
activity-probe for selective measurement of CYP1A1 iso-
Figure 2. Effects of dichloromethane extract of K. galanga L. (DEK) and EPMC on total P450s content (A) and hepatic cytochrome P450,
CYP1A1 (B), CYP1A2 (C), CYP2B (D), CYP2E1 (E) and CYP3A4 (F) activities in mice. Values are expressed as mean ± SD
(n = 5). Columns represent control, 3MC: 3-methylchloranthrene (100mg/kg),  PB: Phenobarbital (100mg/kg), PCN: Pregneno-
lone 16-carbonitrile (50mg/kg), EtOH: Ethanol (10%), DEK (100 mg/kg) and EPMC (120 and 160 mg/kg).
*
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forms, both DEK and EPMC significantly increased CYP1A1
activities in mice (Figure 2B). In contrast, the methoxyreso-
rufin O-dealkylation (MROD) that represented CYP1A2
activities  of  the  DEK  and  EPMC  treated  groups  did  not
change (Figure 2C). For positive control groups, a specific
inducer, 3-MC, administration markedly increased CYP1A1
and CYP1A2 activities up to 6.3- and 9.3- fold, respectively.
Both DEK and EPMC significantly increased the penthoxy-
resorufin O-dealkylase (PROD) reaction, that was a specific
probe for CYP2B. The CYP2B activities were significantly
elevated to 3.18-, 4.22- and 7.66- fold in DEK (100 mg/kg) and
EPMC (120 and 160 mg/kg) treated groups (Figure 2D). For
CYP2E1 activities, DEK (100 mg/kg) and EPMC (120 mg/kg)
did not cause significant difference of the p-nitrophenol
hydroxylase activity (Figure 2E). However, when the concen-
tration of EPMC was increased to 160 mg/kg, CYP2E1 activity
reduced, whereas the CYP3A4 activities of all treated groups
did  not  change  (Figure  2F).  Positive  control  groups,  PB,
EtOH, and PCN significantly elevated CYP2B, CYP2E1 and
CYP3A4 activities to 38-, 2.6-, and 1.6-fold, respectively.
4. Discussion
Regarding the high content of volatile oil in the rhi-
zome, the non-polar dichloromethane extract (DEK) and the
pharmacologically active compound, EPMC, were used for
the investigation of the potential of K. galanga L. for herbal-
drug interaction. The results in the present study showed
that both DEK and EPMC significantly affected P450 content
and the hepatic microsomal CYP enzyme activities in mice.
DEK at 100 mg/kg and EPMC up to 160 mg/mg did not
affect the body or organ weights of mice at 28 consecutive
days of treatment. These results indicate the safety of the
selected  doses  of  K.  galanga  L.  used  in  this  study.  Our
results confirm the previous report on the safety exposures
of ethanolic K. galanga L. extract in rat (Kanjanapothi et al.,
2004). For CYP activities, CYP1A1 and CYP2B were signifi-
cant increased in the DEK-treated group; likewise in the
EPMC-treated group. These findings suggest that EPMC
may contribute at least in part to the induction of CYP1A1
and CYP2B by K. galanga L. However, the effect of these
extracts was lower than that of 3-MC and phenobarbital,
which are specific inducers of CYP1A1 and CYP2B enzyme,
respectively. These results are in agreement with the findings
of previous studies that herbal remedy can interact with
P450 activity, such as Gingko biloba (G. biloba) extract that
markedly inducing CYP2B activity (Umegaki et al., 2002).
The induction of CYP enzyme isoform which is responsible
for the metabolism of a drug can reduce the drugs expected
therapeutic capacity due to depletion of its plasma concen-
tration. For example, G. biloba extract reduced the hypnotic
potency  of  phenobarbital  in  rats,  with  the  reduction  of
phenobarbital Cmax and AUC0-24 (Kubota et al., 2004). Baicalin,
a  flavone  glucuronide  extracted  from  Radix  scutellariae
induced the CYP2B6-catalyzed hydroxylation of bupropion
in  healthy  male  volunteers  (Fan  et  al.,  2009).  Our  result
reveals the effect of DEK and EPMC on CYP1A1 and CYP2B
activity. These findings may suggest a risk of interactions
between K. galanga L. with conventional drugs. Induction of
CYP1A1 and CYP2B activity can decrease drug plasma con-
centrations to sub-therapeutic levels leading to loss of phar-
macological effect. Therefore, co-administration of K. galanga
L. with drugs that metabolize via these CYP isoforms such as
caffeine, phenacetin, warfarin, phenobarbital, cyclophospha-
mide and efavirence should be avoided. In addition, repeat
exposure of this herbal remedy may raise the risk of chemical
carcinogenesis from metabolic activation process via these
CYP such as benzo(a) pyrene, 4-4(bis)methylenechloroani-
line, or alfatoxin B1.
However, inconsistencies between P450 content and
CYPs activities were observed. A significant decrease of total
hepatic P450 content in the present study reflects the changes
of P450 content and these may not represent alteration of
individual CYP isoform content. Moreover, the changes in
each CYP activity suggest the specific induction and inhibi-
tion  of  DEK  and  EPMC  treatment  since  CYP1A1  and
CYP2B6 had rather low expression when compared to other
human  P450s  (Zanger  and  Erichelbaum,  2000;  Yan  and
Caldwell, 2001). The induction of these two CYPs by DEK
and  EPMC  may  not  much  contribute  to  the  total  P450s
content. Furthermore, whether or not change in the other
CYPs activities participate in the reduction of P450 content
needs to be further investigated.
The findings that DEK or EPMC did not have modu-
latory effect on CYP3A4 and CYP1A2 activities in this study
may suggest certain safety of this plant on herbal-drug inter-
action  and  human  risk  assessment  on  chemical  carcino-
genesis as more than 50% of conventional drugs are metabo-
lized via these CYP isoforms. For example, theophylline,
imipramine, propranolol are metabolized by CYP1A2 and
cyclosporine, erythromycin, simvastatin are metabolized by
CYP3A4 (Anzenbacher and Anzenbacherrova, 2001). Addi-
tionally, slight reduction of CYP2E1 activity may suggest
slight anti-carcinogenic activity of EPMC. Regarding CYP2E1
is involved in metabolic activation of many low molecular
weight toxins and carcinogen such as carbon tetrachloride,
chloroform, methylchloride, vinylchloride (Anzenbacher and
Anzenbacherrova, 2001). Inhibition of this enzyme activity
may decrease risk of chemical-induced toxicity, mutagenesis,
and carcinogenesis.
5. Conclusion
In conclusion, the results demonstrate induction of
CYP1A1  and  CYP2B  by  DEK  and  EPMC  in  mice,  which
indicate the possible role of K. galanga L. in herbal-drug
interaction. However, to indicate a clinical significance, the
potential interaction between DEK or EPMC and CYP1A1 or
CYP2B substrates needs to be further investigated.W. Sirisangtragul & B. Sripanidkulchai / Songklanakarin J. Sci. Technol. 33 (4), 411-417, 2011 416
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